• 1
    Nass SJ, Moses HL, Mendelsohn J. A National Cancer Clinical Trials System for the 21st Century; Reinvigorating the NCI Cooperative Group Program. Washington, DC: Institute of Medicine, 2010; 317.
  • 2
    Adamson P. 2011.
  • 3
    Lamont EB, Herndon JE, 2nd, Weeks JC, et al. Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. Med Care 2008; 46(3): 303308.
  • 4
    Lamont EB, Herndon JE, 2nd, Weeks JC, et al. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst 2006; 98(18): 13351338.
  • 5
    Lamont EB, Herndon JE, 2nd, Weeks JC, et al. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst 2005, 97(14): 10801083.
  • 6
    Fisher BT, Aplenc R, Localio R, et al. Cefepime and mortality in pediatric acute myelogenous leukemia: a retrospective cohort study. Pediatr Infect Dis J 2009; 28(11): 971975.
  • 7
    Fisher BT, Zaoutis TE, Leckerman KH, et al. Risk factors for renal failure in pediatric patients with acute myeloid leukemia: a retrospective cohort study. Pediatr Blood Cancer 2010; 55(4): 655661.
  • 8
    Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: A report from the children's oncology group. Cancer 2012; 118(3): 761769.
  • 9
    Ries L, Smith M, Gurney J, et al. (eds). Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975–1995. National Cancer Institute: Bethesda, MD, 1999; 182.
  • 10
    Sung L, Aplenc R, Zaoutis T, et al. Infections in pediatric acute myeloid leukemia: lessons learned and unresolved questions. Pediatr Blood Cancer 2008; 51(4): 458460.
  • 11
    Rosenman MB, Vik T, Hui SL, et al. Hospital resource utilization in childhood cancer. J Pediatr Hematol Oncol 2005; 27(6): 295300.
  • 12
    Mahoney MR, Sargent DJ, O'Connell MJ, et al. Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials. J Clin Oncol 2005; 23(36): 92759281.
  • 13
    Scharf O, Colevas AD. Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol 2006; 24(24): 39333938.
  • 14
    Kaiser LD, Melemed AS, Preston AJ, et al. Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications. J Clin Oncol 28(34): 50465053.
  • 15
    Zaoutis T, Localio AR, Leckerman K, et al. Prolonged intravenous therapy versus early transition to oral antimicrobial therapy for acute osteomyelitis in children. Pediatrics 2009; 123(2): 636642.
  • 16
    Newman K, Ponsky T, Kittle K, et al. Appendicitis 2000: variability in practice, outcomes, and resource utilization at thirty pediatric hospitals. J Pediatr Surg 2003; 38(3): 372379; discussion 372–9.
  • 17
    Benchimol EI, Manuel DG, To T, et al. Development and use of reporting guidelines for assessing the quality of validation studies of health administrative data. J Clin Epidemiol 64(8): 821829.